2 terminated, 1 completed, 1 withdrawn. 4 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 4 | Terminated 2, Completed 1, Withdrawn 1 |
Follow Breast Neoplasm: new trials by email Literature Review of Breast Neoplasm trials Research Report on Breast Neoplasm
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Impact of eHealth-support on Quality of Life in Metastatic Breast Cancer Patients Treated With Palbociclib and Endocrine Therapy Palbociclib, Fulvestrant, Anastrozole - Breast Neoplasm | Phase 4 | Terminated | Palleos Healthcare GmbH | 532 | 2017-07-24 | 2022-01-06 |
| Comparison of FlexHD and Alloderm Outcomes in Breast Reconstructive Surgery FlexHD, Alloderm - Breast Neoplasm | Phase 4 | Withdrawn | University of Arkansas | 2016-03-01 | 2018-07-18 | |
| Will Preoperative MRI Breast in Women Under 56 Years With Breast Cancer Change Primary Treatment MRI - Breast Neoplasm | Phase 4 | Completed | Karolinska University Hospital | 440 | 2008-02-01 | 2013-05-29 |
| Safety Study of CAELYX in Patients With Metastatic Breast Cancer Previously Treated With Anthracyclines (Study P04057)(TERMINATED) Pegylated Liposomal Doxorubicin - Breast Neoplasm | Phase 4 | Terminated | Merck Sharp & Dohme LLC | 1 | 2006-02-01 | 2015-07-14 |
Breast Neoplasms (4) · Neoplasm Metastasis (1)
Breast Diseases (4) · Neoplasms (4) · Neoplasms by Site (4) · Skin Diseases (4) · Skin and Connective Tissue Diseases (4) · Neoplastic Processes (1) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1)
Alloderm (1) · Anastrozole (1) · FlexHD (1) · Fulvestrant (1) · Letrozole (1) · exemestane (1) · liposomal doxorubicin (1) · palbociclib (1)
Karolinska University Hospital (1) · Merck Sharp & Dohme LLC (1) · Palleos Healthcare GmbH (1) · University of Arkansas (1)
Germany (1) · Sweden (1) · United States (1)
Brita Arver, MD PhD (1) · Iris Reiser, PhD (1) · Pallavi A Kumbla, MD (1)